CU20090025A7 - Inhibidores de la metaloproteinasa matriz - Google Patents
Inhibidores de la metaloproteinasa matrizInfo
- Publication number
- CU20090025A7 CU20090025A7 CU20090025A CU20090025A CU20090025A7 CU 20090025 A7 CU20090025 A7 CU 20090025A7 CU 20090025 A CU20090025 A CU 20090025A CU 20090025 A CU20090025 A CU 20090025A CU 20090025 A7 CU20090025 A7 CU 20090025A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- present
- carboxylic acids
- inhibitors
- matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
El presente invento se rerlaciona con ácidos carboxílicos sustituidos mediante B-hidroxi y amino, que actúan como inhibidores de la metaloproteasa matriz, ácidos carboxílicos B-hidroxi diastereoméricamente puros, procesos correspondientes para la síntesis de composiciones farmacéuticas que contienen los compuestos del presente invento. Los compuestos del presente invento son útiles en el tratamiento de diversas enfermedades inflamatorias, de autoinmunidad y alérgicas , como ser los métodos para tratar el asma, la artritis reumatoidea, COPD, rinitis, osteoartritis, artritis soriásica, psoriasis, fibrosis pulmonar, desórdenes en la cura de heridas, inflamación pulmonar, síndrome de perturbación respiratoria agudo, periodontitis, esclerosis múltiple, gingivitis, ateroesclerosis, proliferación neoíntima, que lleva a la restenosis y a la insuficiencia cardíaca isquémica, ataque apopléjico, enfermedades renales, metástasis tumoral y otros desódenes inflamatorios caracterizados por la hiperexpresión e hiper-activación de una metaloproteinasa matriz utilizando los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1880DE2006 | 2006-08-22 | ||
PCT/IB2007/053340 WO2008023336A2 (en) | 2006-08-22 | 2007-08-21 | Matrix metalloproteinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20090025A7 true CU20090025A7 (es) | 2011-07-11 |
CU23830B1 CU23830B1 (es) | 2012-10-15 |
Family
ID=38961876
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2009000025A CU23830B1 (es) | 2006-08-22 | 2009-02-20 | Inhibidores de la metaloproteinasa matriz |
CU20110134A CU20110134A7 (es) | 2006-08-22 | 2011-06-15 | Inhibidores de la metaloproteinasa matriz |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20110134A CU20110134A7 (es) | 2006-08-22 | 2011-06-15 | Inhibidores de la metaloproteinasa matriz |
Country Status (41)
Country | Link |
---|---|
US (3) | US8507670B2 (es) |
EP (3) | EP2474531A3 (es) |
JP (2) | JP5399902B2 (es) |
KR (1) | KR101467590B1 (es) |
CN (1) | CN101528691B (es) |
AP (1) | AP2690A (es) |
AR (1) | AR063945A1 (es) |
BR (1) | BRPI0715231A2 (es) |
CA (1) | CA2661299A1 (es) |
CL (1) | CL2007002427A1 (es) |
CO (1) | CO6150172A2 (es) |
CR (2) | CR10674A (es) |
CU (2) | CU23830B1 (es) |
CY (1) | CY1113444T1 (es) |
DK (1) | DK2074093T3 (es) |
EA (1) | EA016567B1 (es) |
ES (1) | ES2397284T3 (es) |
GE (1) | GEP20125458B (es) |
HK (1) | HK1135684A1 (es) |
HR (1) | HRP20121079T1 (es) |
IL (2) | IL197097A0 (es) |
JO (1) | JO2868B1 (es) |
MA (1) | MA30674B1 (es) |
ME (1) | ME00594B (es) |
MX (1) | MX2009001963A (es) |
MY (1) | MY155277A (es) |
NI (1) | NI200900028A (es) |
NO (1) | NO20091169L (es) |
NZ (1) | NZ574905A (es) |
PH (1) | PH12012502420A1 (es) |
PL (1) | PL2074093T3 (es) |
PT (1) | PT2074093E (es) |
RS (1) | RS52575B (es) |
SG (1) | SG174089A1 (es) |
SI (1) | SI2074093T1 (es) |
SM (1) | SMP200900018B (es) |
TN (1) | TN2009000054A1 (es) |
TW (2) | TW200817345A (es) |
UA (1) | UA95115C2 (es) |
WO (1) | WO2008023336A2 (es) |
ZA (1) | ZA200901427B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
AP2690A (en) * | 2006-08-22 | 2013-07-15 | Ranbaxy Laboratoiries Ltd | Matrix metalloproteinase inhibitors |
CN103119030A (zh) | 2010-07-30 | 2013-05-22 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
US9115096B2 (en) | 2011-05-10 | 2015-08-25 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
CN103751797B (zh) * | 2013-12-30 | 2015-08-19 | 浙江工业大学 | 一种具有双重疗效的酶触释药制剂、其制备方法及应用 |
CN107567443B (zh) * | 2014-12-24 | 2023-04-28 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
CN110339205B (zh) * | 2019-08-19 | 2021-08-24 | 山东德信生物科技有限公司 | 富氢水组合物在抑制六价铬诱导的df-1细胞内质网应激及自噬中的应用 |
CN110437311B (zh) * | 2019-08-27 | 2022-05-20 | 南京安吉生物科技有限公司 | 一种多肽及其应用 |
US11618761B2 (en) | 2019-11-06 | 2023-04-04 | Nocion Therapeutics, Inc. | Phosphonium ion channel blockers and methods for use |
WO2022266039A1 (en) * | 2021-06-16 | 2022-12-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for monitoring and treating stroke |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1113690B (de) | 1957-02-27 | 1961-09-14 | Merck & Co Inc | Verfahren zur Herstellung von in 11-Stellung durch sauerstoffhaltige Gruppen substituierten 16-Methyl-1, 4-pregnadien-17ª‡-ol-3, 20-dion-Verbindungen |
GB869511A (en) | 1958-05-26 | 1961-05-31 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
US3007923A (en) | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US3937838A (en) * | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
DE2366625C2 (es) | 1972-02-05 | 1988-06-09 | Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp | |
SE378109B (es) * | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US4011258A (en) | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
CY1273A (en) | 1980-07-09 | 1985-03-08 | Draco Ab | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
CA1240708A (en) * | 1983-11-15 | 1988-08-16 | Johannes K. Minderhoud | Process for the preparation of hydrocarbons |
ES2084801T3 (es) * | 1990-02-19 | 1996-05-16 | Ciba Geigy Ag | Acil compuestos. |
GR1001529B (el) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
ATE206416T1 (de) * | 1995-06-02 | 2001-10-15 | Warner Lambert Co | Trizyklische verbindungen als matrix- metalloproteinase inhibitoren |
WO1998009940A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
MY117687A (en) * | 1996-10-31 | 2004-07-31 | Bayer Corp | Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors |
FR2780402B1 (fr) * | 1998-06-30 | 2001-04-27 | Adir | Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU4229499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
HU222773B1 (hu) * | 2000-04-21 | 2003-10-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás egy ismert tetrazolszármazék előállítására |
GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
EA013539B1 (ru) * | 2005-02-22 | 2010-06-30 | Рэнбакси Лабораториз Лимитед | Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний |
AP2690A (en) * | 2006-08-22 | 2013-07-15 | Ranbaxy Laboratoiries Ltd | Matrix metalloproteinase inhibitors |
-
2007
- 2007-08-21 AP AP2009004784A patent/AP2690A/xx active
- 2007-08-21 JP JP2009525162A patent/JP5399902B2/ja not_active Expired - Fee Related
- 2007-08-21 BR BRPI0715231-0A2A patent/BRPI0715231A2/pt not_active IP Right Cessation
- 2007-08-21 SG SG2011060019A patent/SG174089A1/en unknown
- 2007-08-21 GE GEAP200711178A patent/GEP20125458B/en unknown
- 2007-08-21 JO JO2007338A patent/JO2868B1/en active
- 2007-08-21 PL PL07826082T patent/PL2074093T3/pl unknown
- 2007-08-21 KR KR1020097005737A patent/KR101467590B1/ko not_active IP Right Cessation
- 2007-08-21 MX MX2009001963A patent/MX2009001963A/es active IP Right Grant
- 2007-08-21 ES ES07826082T patent/ES2397284T3/es active Active
- 2007-08-21 CA CA002661299A patent/CA2661299A1/en not_active Abandoned
- 2007-08-21 US US12/438,182 patent/US8507670B2/en not_active Expired - Fee Related
- 2007-08-21 EA EA200970214A patent/EA016567B1/ru not_active IP Right Cessation
- 2007-08-21 SI SI200731061T patent/SI2074093T1/sl unknown
- 2007-08-21 WO PCT/IB2007/053340 patent/WO2008023336A2/en active Application Filing
- 2007-08-21 DK DK07826082.5T patent/DK2074093T3/da active
- 2007-08-21 RS RS20120558A patent/RS52575B/en unknown
- 2007-08-21 NZ NZ574905A patent/NZ574905A/en not_active IP Right Cessation
- 2007-08-21 MY MYPI20090639A patent/MY155277A/en unknown
- 2007-08-21 CL CL200702427A patent/CL2007002427A1/es unknown
- 2007-08-21 EP EP12163184.0A patent/EP2474531A3/en not_active Withdrawn
- 2007-08-21 EP EP07826082A patent/EP2074093B1/en active Active
- 2007-08-21 ME MEP-2009-59A patent/ME00594B/me unknown
- 2007-08-21 EP EP10196009.4A patent/EP2322507A1/en not_active Withdrawn
- 2007-08-21 CN CN200780038726.2A patent/CN101528691B/zh not_active Expired - Fee Related
- 2007-08-21 PT PT78260825T patent/PT2074093E/pt unknown
- 2007-08-21 UA UAA200902501A patent/UA95115C2/ru unknown
- 2007-08-22 TW TW096131028A patent/TW200817345A/zh unknown
- 2007-08-22 TW TW102120084A patent/TW201336829A/zh unknown
- 2007-08-22 AR ARP070103738A patent/AR063945A1/es unknown
-
2009
- 2009-02-17 IL IL197097A patent/IL197097A0/en unknown
- 2009-02-20 CU CU2009000025A patent/CU23830B1/es active IP Right Grant
- 2009-02-20 TN TN2009000054A patent/TN2009000054A1/fr unknown
- 2009-02-23 CO CO09017757A patent/CO6150172A2/es unknown
- 2009-02-27 MA MA31675A patent/MA30674B1/fr unknown
- 2009-02-27 ZA ZA200901427A patent/ZA200901427B/xx unknown
- 2009-03-04 NI NI200900028A patent/NI200900028A/es unknown
- 2009-03-16 SM SM200900018T patent/SMP200900018B/it unknown
- 2009-03-19 NO NO20091169A patent/NO20091169L/no not_active Application Discontinuation
- 2009-03-20 CR CR10674A patent/CR10674A/es unknown
- 2009-12-17 HK HK09111893.6A patent/HK1135684A1/xx not_active IP Right Cessation
-
2011
- 2011-06-15 CU CU20110134A patent/CU20110134A7/es unknown
-
2012
- 2012-06-13 IL IL220353A patent/IL220353A0/en unknown
- 2012-12-05 PH PH12012502420A patent/PH12012502420A1/en unknown
- 2012-12-10 CY CY20121101194T patent/CY1113444T1/el unknown
- 2012-12-28 HR HRP20121079TT patent/HRP20121079T1/hr unknown
-
2013
- 2013-02-19 JP JP2013030107A patent/JP2013151500A/ja active Pending
- 2013-07-08 US US13/936,439 patent/US8846910B2/en not_active Expired - Fee Related
- 2013-07-08 US US13/936,382 patent/US8816073B2/en not_active Expired - Fee Related
-
2014
- 2014-09-08 CR CR20140412A patent/CR20140412A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23830B1 (es) | Inhibidores de la metaloproteinasa matriz | |
EA201390404A1 (ru) | Ингибиторы матричной металлопротеиназы | |
CY1122895T1 (el) | Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος | |
CY1115203T1 (el) | Προφαρμακα οξινου φουμαρικου μεθυλ εστερα, φαρμακευτικες συνθεσεις αυτων και μεθοδοι χρησης | |
NI201000033A (es) | Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis | |
UY29839A1 (es) | Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones. | |
CY1121825T1 (el) | Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου | |
PE20150224A1 (es) | Inhibidores del nampt | |
NI200700296A (es) | Imidazoquinolinas como inhibidores de cinasa de lipido | |
EA201390405A1 (ru) | Ингибиторы матричной металлопротеиназы | |
UY30287A1 (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
EA200901289A1 (ru) | Композиции и способы для противовосполительного лечения | |
CU24103B1 (es) | Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos | |
BR112015010512A2 (pt) | derivados de carboxamida de 3-aminociclopentano | |
CU23718B7 (es) | Derivados del ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa de la matriz. | |
NI201400017A (es) | 2 - (croman - 6 - iloxi ) - tiazoles sustituidos y su uso como productos farmacéuticos | |
BR112012014860A2 (pt) | pró-fármacos de [4 [4-(5-aminometil-2-flúor-fenil)-piperidin-1-il]-(1h-pirrolo-piridin-il)-metanonas e sua síntese | |
EA201391155A1 (ru) | Ингибитор катепсина с | |
TH153693A (th) | อะมิโนแอซาเฮเทอโรไซคลิคคาร์บอกแซมีดชนิดใหม่ | |
UA90523C2 (ru) | 4-бензиламино-1-фенил-1,5-дигидропирол-2-он, который проявляет анальгетическую и противовоспалительную активность | |
CU20100040A7 (es) | Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis | |
TH96596A (th) | ตัวยับยั้งปฏิกิริยาเมตริกซ์เมทัลโลโปรตีเนส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |